Noninfectious HIV-Related Comorbidities and Haart Toxicities: Choosing Alternative Antiretroviral Strategies

• Palella FJ , DelaneyK, MoormanAet al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N. Engl. J. Med.338(13), 853–860(1998).
   PubMed Web of Science ®Google Scholar
• Mocroft A , VellaS, BenfieldTet al.: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.Lancet352(9142), 1725–1730(1998).
   PubMed Web of Science ®Google Scholar
• d‘Arminio Monforte A , SabinC, PhillipsAet al.: The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.Arch. Intern. Med.165(4), 416–423(2005).
   PubMedGoogle Scholar
• Collaboration ATC: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet372(9635), 293–299(2008).
   PubMed Web of Science ®Google Scholar
• Obel N , ThomsenH, KronborgGet al.: Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study.Clin. Infect. Dis.44(12), 1625–1631(2007).
   PubMed Web of Science ®Google Scholar
• Klein D , HurleyL, QuesenberryCJ, SidneyS: Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?J. Acquir. Immune Defic. Syndr.30(5), 471–477(2002).
   PubMed Web of Science ®Google Scholar
• Currier J , TaylorA, BoydFet al.: Coronary heart disease in HIV-infected individuals.J. Acquir. Immune Defic. Syndr.33(4), 506–512(2003).
   PubMed Web of Science ®Google Scholar
• Brown T , QaqishR: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.AIDS20(17), 2165–2174(2006).
   PubMed Web of Science ®Google Scholar
• Odden M , ScherzerR, BacchettiPet al.: Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study.Arch. Intern. Med.167(20), 2213–2219(2007).
   PubMedGoogle Scholar
• Lohse N , HansenA, PedersenGet al.: Survival of persons with and without HIV infection in Denmark, 1995–2005.Ann. Intern. Med.146(2), 87–95(2007).
   PubMed Web of Science ®Google Scholar
• Dubé M , SattlerF: Inflammation and complications of HIV disease.J. Infect. Dis.201(12), 1783–1785(2010).
   PubMed Web of Science ®Google Scholar
• Desai S , LandayA: Early immune senescence in HIV disease.Curr. HIV/AIDS Rep.7(1), 4–10(2010).
   PubMedGoogle Scholar
• Appay V , SauceD: Immune activation and inflammation in HIV-1 infection: causes and consequences.J. Pathol.214(2), 231–241(2008).
   PubMed Web of Science ®Google Scholar
• Desquilbet L , JacobsonL, FriedLet al.: HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty.J. Gerontol. A. Biol. Sci. Med. Sci.62(11), 1279–1286(2007).
   PubMed Web of Science ®Google Scholar
• Deeks S , PhillipsA: HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.BMJ338, A3172 (2009).
   PubMed Web of Science ®Google Scholar
• Carr A , CooperD: Adverse effects of antiretroviral therapy.Lancet356(9239), 1423–1430(2000).
   PubMed Web of Science ®Google Scholar
• Reisler R , HanC, BurmanW, TedaldiE, NeatonJ: Grade 4 events are as important as AIDS events in the era of HAART.J. Acquir. Immune Defic. Syndr.34(4), 379–386(2003).
   PubMed Web of Science ®Google Scholar
• El-Sadr W , LundgrenJ, NeatonJet al.: CD4+ count-guided interruption of antiretroviral treatment.N. Engl. J. Med.355(22), 2283–2296(2006).
   PubMed Web of Science ®Google Scholar
• Villarroya F , DomingoP, GiraltM: Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment.Biochim. Biophys. Acta1801(3), 392–399(2010).
   PubMed Web of Science ®Google Scholar
• Haubrich R , RiddlerS, Di Rienzo G et al.: Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS23(9), 1109–1118(2009).
   PubMed Web of Science ®Google Scholar
• Hadigan C , CorcoranC, StanleyTet al.: Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J. Clin. Endocrinol. Metab.85(1), 35–41(2000).
   PubMed Web of Science ®Google Scholar
• De Wit S , SabinC, WeberRet al.: Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care31(6), 1224–1229(2008).
   PubMed Web of Science ®Google Scholar
• Yan Q , HruzP: Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.J. Acquir. Immune Defic. Syndr.40(4), 398–403(2005).
   PubMed Web of Science ®Google Scholar
• Noor M , FlintO, MaaJ, ParkerR: Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically.AIDS20(14), 1813–1821(2006).
   PubMed Web of Science ®Google Scholar
• Mills A , NelsonM, JayaweeraDet al.: Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.AIDS23(13), 1679–1688(2009).
   PubMed Web of Science ®Google Scholar
• Mallolas J , PodzamczerD, MilinkovicAet al.: Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.J. Acquir. Immune Defic. Syndr.51(1), 29–36(2009).
   PubMed Web of Science ®Google Scholar
• El Hadri K , GlorianM, MonsempesCet al.: In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes.J. Biol. Chem.279(15), 15130–15141(2004).
   PubMed Web of Science ®Google Scholar
• Friis-M⊘ller N , SabinC, WeberRet al.: Combination antiretroviral therapy and the risk of myocardial infarction.N. Engl. J. Med.349(21), 1993–2003(2003).
   PubMed Web of Science ®Google Scholar
• Friis-M⊘ller N , ReissP, SabinCet al.: Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med.356(17), 1723–1735(2007)
   PubMed Web of Science ®Google Scholar
• Worm S , SabinC, WeberRet al.: Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.J. Infect. Dis.201(3), 318–330(2010).
   PubMed Web of Science ®Google Scholar
• Lang S , Mary-KrauseM, CotteLet al.: Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case–control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch. Intern. Med.170(14), 1228–1238(2010).
   PubMedGoogle Scholar
• Lundgren J , NeuhausJ, BabikerAet al.: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART study. Presented at: IAS. Mexico City, Mexico, 3–8 August, 2008.
   Google Scholar
• Durand M , SheehyO, BarilJGet al.: Relation between use of nucleoside reverse transcriptase inhibitors (NRTI) and risk of myocardial infarction (MI): a nested case control study using Quebec‘s public health insurance database (QPHID). Presented at: IAS. Cape Town, South Africa, 19–22 July 2009.
   Google Scholar
• Brothers C , HernandezJ, CutrellAet al.: Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J. Acquire. Immune Defic. Syndr.51(1), 20–28(2009).
   PubMed Web of Science ®Google Scholar
• Benson C , RibaudoH, ZhengEet al.: No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. Presented at: 16th CROI. Montreal, Canada, 8–11 February 2009.
   Google Scholar
• Currier J : Update on cardiovascular complications in HIV infection.Top. HIV Med.17(3), 98–103(2009).
   PubMedGoogle Scholar
• Gallant J , StaszewskiS, PozniakAet al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA292(2), 191–201(2004).
   PubMed Web of Science ®Google Scholar
• Mallon P , MillerJ, CooperD, CarrA: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.AIDS17(7), 971–979(2003).
   PubMed Web of Science ®Google Scholar
• McComsey G , KitchD, DaarEet al.: Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded Phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. Presented at: 17th CROI. San Francisco, CA, USA, 16–19 February 2010.
   Google Scholar
• Röling J , SchmidH, FischerederM, DraenertR, GoebelF: HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.Clin. Infect. Dis.42(10), 1488–1495(2006).
   PubMed Web of Science ®Google Scholar
• Daugas E , RougierJ, HillG: HAART-related nephropathies in HIV-infected patients.Kidney Int.67(2), 393–403(2005).
   PubMed Web of Science ®Google Scholar
• Chugh S , BirdR, AlexanderE: Ritonavir and renal failure.N. Engl. J. Med.336(2), 138 (1997).
   PubMed Web of Science ®Google Scholar
• Green S , McKendrickM, SchmidM, MohsenA, PrakasamS: Renal calculi developing de novo in a patient taking saquinavir.Int. J. STD AIDS9(9), 555 (1998).
   PubMed Web of Science ®Google Scholar
• Engeler D , JohnH, RentschK, RuefC, OertleD, SuterS: Nelfinavir urinary stones.J. Urol.167(3), 1384–1385(2002).
   PubMed Web of Science ®Google Scholar
• Brewster U , PerazellaM: Acute interstitial nephritis associated with atazanavir, a new protease inhibitor.Am. J. Kidney Dis.44(5), E81–E84 (2004).
   PubMed Web of Science ®Google Scholar
• Pacanowski J , PoirierJM, PetitI, MeynardJL, GirardPM: Atazanavir urinary stones in an HIV-infected patient.AIDS.20(16), 2131 (2006).
   PubMed Web of Science ®Google Scholar
• Chang HR , PellaPM: Atazanavir urolithiasis.N. Engl. J. Med.355(20), 2158–2159(2006).
   PubMed Web of Science ®Google Scholar
• Anderson PL , LichtensteinKA, GerigNE, KiserJJ, BushmanLR: Atazanavir-containing renal calculi in an HIV-infected patient.AIDS.21(8), 1060–1062(2007).
   PubMed Web of Science ®Google Scholar
• Mocroft A , KirkO, ReissPet al.: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS.24(11), 1667–1678(2010).
   PubMed Web of Science ®Google Scholar
• Barrios A , García-BenayasT, González-LahozJ, SorianoV: Tenofovir-related nephrotoxicity in HIV-infected patients.AIDS18(6), 960–963(2004).
   PubMed Web of Science ®Google Scholar
• Peyrière H , ReynesJ, RouanetIet al.: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.J. Acquir. Immune Defic. Syndr.35(3), 269–273(2004).
   PubMed Web of Science ®Google Scholar
• Mauss S , BergerF, SchmutzG: Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.AIDS19(1), 93–95(2005).
   PubMed Web of Science ®Google Scholar
• Squires K , PozniakA, PieroneGJet al.: Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.Ann. Intern. Med.139(5 Pt 1), 313–320(2003).
   PubMed Web of Science ®Google Scholar
• Jones R , StebbingJ, NelsonMet al.: Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.J. Acquir. Immune Defic. Syndr.37(4), 1489–1495(2004).
   PubMed Web of Science ®Google Scholar
• Cossarizza A , MoyleG: Antiretroviral nucleoside and nucleotide analogues and mitochondria.AIDS18(2), 137–151(2004).
   PubMed Web of Science ®Google Scholar
• Lonergan J , BehlingC, PfanderH, HassaneinT, MathewsW: Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens.Clin. Infect. Dis.31(1), 162–166(2000).
   PubMed Web of Science ®Google Scholar
• Joly V , YeniP: Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.Antivir. Ther.10(1), 29–40(2005).
   PubMed Web of Science ®Google Scholar
• Staszewski S , Morales-RamirezJ, TashimaKet al.: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.N. Engl. J. Med.341(25), 1865–1873(1999).
   PubMed Web of Science ®Google Scholar
• Negredo E , MoltóJ, BurgerDet al.: Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).J. Acquir. Immune Defic. Syndr.38(1), 47–52(2005).
   PubMed Web of Science ®Google Scholar
• Negredo E , MiróO, Rodríguez-SantiagoBet al.: Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).Clin. Infect. Dis.49(6), 892–900(2009).
   PubMed Web of Science ®Google Scholar
• Harris M , CotéH, OchoaCet al.: A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.J. Acquir. Immune Defic. Syndr.50(3), 335–337(2009).
   PubMed Web of Science ®Google Scholar
• Allavena C , FerréV, Brunet-FrançoisCet al.: Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.J. Acquir. Immune Defic. Syndr.39(3), 300–306(2005).
   PubMed Web of Science ®Google Scholar
• Riddler S , HaubrichR, DiRienzoAet al.: Class-sparing regimens for initial treatment of HIV-1 infection.N. Engl. J. Med.358(20), 2095–2106(2008).
   PubMed Web of Science ®Google Scholar
• Arribas J , PulidoF, DelgadoRet al.: Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).J. Acquir. Immune Defic. Syndr.40(3), 280–287(2005).
   PubMed Web of Science ®Google Scholar
• Pulido F , ArribasJ, DelgadoRet al.: Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.AIDS22(2), F1–F9 (2008).
   PubMed Web of Science ®Google Scholar
• Cameron D , da SilvaB, ArribasJet al.: A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J. Infect. Dis.198(2), 234–240(2008).
   PubMed Web of Science ®Google Scholar
• Bierman W , van AgtmaelM, NijhuisM, Danner S, Boucher C: HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS23(3), 279–291(2009).
   PubMed Web of Science ®Google Scholar
• Delfraissy J , FlandreP, DelaugerreCet al.: Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.AIDS22(3), 385–393(2008).
   PubMed Web of Science ®Google Scholar
• Karlstrom O , JosephsonF, SonnerborgA: Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.J. Acquir. Immune Defic. Syndr.44(4), 417–422(2007)
   PubMed Web of Science ®Google Scholar
• Wilkin TJ , McKinnonJE, DiRienzoAGet al.: Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy : final 48-week clinical and virologic outcomes. J. Infect. Dis.199(6), 866–871(2009).
   PubMed Web of Science ®Google Scholar
• Arribas J , HorbanA, GerstoftJet al.: The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-RNA below 50 copies/ml. AIDS24(2), 223–230(2010).
   PubMed Web of Science ®Google Scholar
• Katlama C , ValentinM, Algarte-GeninM: Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. Presented at: IAS. Cape Town, South Africa, 19–22 July 2009.
   Google Scholar
• Clumeck N , DedesN, PozniakA; EACS Executive Committee: Guidelines for clinical management and treatment of HIV infected adults in Europe, version 5. Presented at: 12th EACS. Cologne, Germany, 11–14 November 2009.
   Google Scholar
• Lennox J , DejesusE, BergerDet al.: Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.J. Acquir. Immune Defic. Syndr.55(1), 39–48(2010).
   PubMed Web of Science ®Google Scholar
• Steigbigel R , CooperD, KumarPet al.: Raltegravir with optimized background therapy for resistant HIV-1 infection.N. Engl. J. Med.359(4), 339–354(2008).
   PubMed Web of Science ®Google Scholar
• Eron J , YoungB, CooperDet al.: Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.Lancet375(9712), 396–407(2010).
   PubMed Web of Science ®Google Scholar
• Martinez E , LarrousseM, LlibreJMet al.: Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS.24(11), 1697–1707(2010).
   PubMed Web of Science ®Google Scholar
• Moltó J , Sanz-MorenoJ, ValleMet al.: Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.Antimicrob. Agents Chemother.54(7), 3047–3048(2010).
   PubMed Web of Science ®Google Scholar
• Cocchi S , BonucchiD, PulizziR: Raltegravir and enfuvirtide as a ‘bridge’ antiretroviral therapy in kidney-transplanted patients with HIV infection receiving everolimus and low-dose cyclosporine: a case–control study. Presented at: ICAR. Brescia, Italy, 20–22 June 2010.
   Google Scholar
• Zhu L , MahnkeL, ButtertonJ: Pharmacokinetics and safety of twice-daily atazanavir (300mg) and raltegravir (400mg) in healthy subjects. Presented at: 16th CROI. Montreal, Canada, 8–11 February 2009.
   Google Scholar
• Ripamonti D , MaggioloF, BombanaE: Efficacy, safety and tolerability of dual therapy with raltegravir and atazanavir in antiretroviral experienced patients. Presented at: IAS. Cape Town, South Africa, 19–22 July 2009.
   Google Scholar
• Gulick R , LalezariJ, GoodrichJet al.: Maraviroc for previously treated patients with R5 HIV-1 infection.N. Engl. J. Med.359(14), 1429–1441(2008).
   PubMed Web of Science ®Google Scholar
• Saag M , PrudenceI, HeeraJ: A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study. Presented at: IAS. Sidney, Australia, 22–25 July 2007.
   Google Scholar
• Quinones M , MartinezH, JimenezFet al.: CC chemokine receptor 5 influences late-stage atherosclerosis.Atherosclerosis195(1), E92–E103 (2007).
   PubMedGoogle Scholar
• Zernecke A , LiehnE, GaoJ, KuzielW, MurphyP, WeberC: Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10.Blood107(11), 4240–4243(2006).
   PubMed Web of Science ®Google Scholar
• Veillard N , KwakB, PelliGet al.: Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice.Circ. Res.94(2), 253–261(2004).
   PubMed Web of Science ®Google Scholar
• Gibellini D , De CrignisE, PontiCet al.: HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFa activation. J. Med. Virol.80(9), 1507–1514(2008).
   PubMed Web of Science ®Google Scholar
• Corbeau P , ReynesJ. CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS23(15), 1931–1943(2009).
   PubMed Web of Science ®Google Scholar
• Mills A , MildvanD, PodzamczerDet al.: Once-daily maraviroc (MVC) + atazanavir/ritonavir (ATV/r) vs emtricitabine/tenofovir (TDF/FTC) + ATV/r in treatment naive patients: a week 24 planned interim analysis. Presented at: IAS. Vienna, Austria, 18–23 July 2010.
   Google Scholar

Website

• DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. DC: Department of Health and Human Services, Washington, DC, USA, 2009 www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
   Google Scholar